1	Rapid detection of myeloid neoplasm fusions using Single Molecule Long-Read Sequencing
2	Olga Sala-Torra MD <sup>1,3</sup> , Shishir Reddy <sup>3</sup> , Ling-Hong Hung <sup>3</sup> , Lan Beppu <sup>1</sup> , David Wu <sup>2</sup> , Jerald Radich,
3	MD <sup>1,2</sup> , Ka Yee Yeung <sup>3</sup> , Cecilia CS Yeung, MD <sup>1,2</sup>
4	
5	<sup>1</sup> Fred Hutchinson Cancer Research Center, Seattle, WA
6	<sup>2</sup> University of Washington, Seattle, WA
7	<sup>3</sup> School of Engineering and Technology, University of Washington Tacoma, Tacoma, WA
8	
9	
10	Keywords (6): Long-read sequencing, CRISPR-Cas9, myeloid neoplasm, nanopore, CML,
11	sequencing
12	
13	Short Title: Long-Read Sequencing for Myeloid Neoplasm Fusions
14	
15	Address correspondence to:
16	Cecilia Yeung, MD
17	1100 Fairview Ave N, G7-910
18	Seattle, WA 98109
19	cyeung@fredhutch.org
20	
21	Key points:

22	1)	We describe a CRISPR-Cas9 enrichment Nanopore sequencing assay with streamlined
23		bioinformatics that outperforms other fusion detectors.
24	2)	We successfully detected both fusion genes and specific breakpoints in CML, APL, and
25		AML in under 8 hours in 80% of patients.
26		
27	Visual	Abstract (Figure 1):
28	1)	We successfully detected fusion genes in hematological malignancies with a fast and
29		efficient long-read sequencing workflow in under 8 hours. The method makes the
30		genomic characterization of BCR-ABL1 DNA breakpoint in patients quick and simple,
31		which potentiates design of patient specific primers for personalized monitoring MRD
32		assays.
33	2)	Our assay is based on a CRISPR-Cas9 non-amplification enrichment library preparation
34		strategy and uses Nanopore sequencing single stranded genomic DNA coupled with
35		streamlined bioinformatic workflow containing a novel fusion detector software which
36		outperforms current fusion detection software.
37		
38	Abstra	ict
39	Recurr	ent gene fusions are common drivers of disease pathophysiology in leukemia:

Recurrent gene fusions are common drivers of disease pathophysiology in leukemias. Identification of these structural variants helps stratify disease by risk and assists with therapy choice. Current fusion detection methods require long turnaround time (7-10 days) or advance knowledge of the genes involved in the fusions. To address the need for rapid identification of clinically actionable fusion genes in heme malignancies without *a-priori* knowledge of the

44 genes, we describe a long-read sequencing DNA assay designed with CRISPR guides to select 45 and enrich for recurrent leukemia fusion genes. By applying rapid sequencing technology based 46 on nanopores, we sequenced long pieces of genomic DNA and successfully detected fusion 47 genes in cell lines and primary specimens (e.g., BCR-ABL1, PML-RARA, CBFB-MYH11, KMT2A-AF4) using cloud-based bioinformatics workflows with novel custom fusion finder software. We 48 49 detected fusion genes in 100% of cell lines with the expected breakpoints and confirmed the 50 presence or absence of a recurrent fusion gene in 12 of 14 patient cases. With our optimized assay and cloud-based bioinformatics workflow, these assays and analyses could be performed 51 52 in under 8 hours.

53

#### 54 Introduction

55 Current classification of myeloid malignancies is largely based on the molecular and genetic aberrations <sup>1,2</sup>. Recurrent gene rearrangements are present in 30-40% of acute myeloid 56 57 leukemias (AML), and well described driver fusions that in some cases suffice to diagnose leukemias with PML-RARA, RUNX1-RUNX1T1, etc. even when the blast percentage is below 58 20%<sup>1</sup>. Recurrent fusion genes confer certain clinical and biological characteristics as drivers of 59 60 leukemogenesis, and their identification assists in prognosis stratification and inform treatment 61 decisions. Identification of driver fusion genes is especially relevant when targeted therapies 62 are available. Examples include tyrosine kinase inhibitors (TKI) in chronic myelogenous leukemia (CML)<sup>3</sup> that bind to the kinase domain in ABL1 deregulated as a consequence of the fusion with 63 64 BCR, and differentiation therapy in acute promyelocytic leukemia (APL) in which identification of the promyelocytic leukemia- retinoic acid receptor alpha (PML-RARA) fusion confirms the 65

diagnosis and indicates that the patient will likely respond to treatment with all-trans retinoic
 acid (ATRA) therapy, a nontoxic and highly effective treatment<sup>4</sup> that achieves 90% long term
 survival rates when combined with anthracyclines and/or arsenic trioxide.<sup>5</sup>

69

70 Fusion genes can be detected through several techniques that include cytogenetics techniques 71 such as fluorescence in situ hybridization (FISH), and molecular testing such as polymerase 72 chain reaction (PCR) and next generation sequencing (NGS), which are the clinical gold 73 standard. Clinical molecular assays for BCR-ABL1 and PML-RARA primarily target RNA 74 transcripts by RT-PCR because of the greater abundance of fusion gene transcripts compared to 75 the DNA copies per cell, and because of the large variability in the genomic sequence of the 76 fusion that can encompass large intronic region making routine DNA PCR impossible (e.g., BCR-77 ABL).

78

79 Typical NGS reads are 150 to 250 bps in length which are not sufficiently long enough to extend 80 over DNA fragments that are adjoined because of a large genomic aberration thus hindering 81 both alignment and detection of large indels and other structural abnormalities. NGS is limited 82 by short read assembly mis-mapping, and amplification strategies instill imperfect quantitation 83 of the variant allele frequencies. The diversity of aberrations in myeloid neoplasms include 84 large genomic aberrations, including insertions and deletions, loss of heterozygosity, single 85 nucleotide polymorphism, mutations in homopolymer rich regions and highly repetitive regions 86 such as internal tandem duplications, that are difficult to detect by NGS and require different assays in molecular and cytogenetics labs additionally to those used to confirm fusion genes. 87

Hence, currently a multiple assay approach is used to obtain a complete diagnostic molecular
picture in myeloid malignancies.

90

91 The advancement of long-read sequencing technologies has enabled the sequencing of continuous single DNA or RNA molecules up to tens to hundreds of kilobases (kb) long.<sup>6</sup> 92 93 Ongoing improvements in Nanopore sequencing accuracy have reduced error rates to less than 5%,<sup>7</sup> but remain higher than those for Illumina and Ion Torrent, which are used frequently in 94 clinical laboratories.<sup>8</sup> This technology has already made an impact on the understanding of the 95 96 pathobiology of various diseases,<sup>9,10</sup> and its impact will increase as the quality of sequencing improves and becomes more accurate.<sup>7,11</sup> Addition of CRISPR-Cas9 for targeted enrichment 97 concentrates the regions of interests prior to sequencing by Nanopore<sup>12</sup> without requiring 98 99 amplification steps, thus optimizing sequencing time and efficiency. Additionally, the portability and affordability of the Nanopore sequencer MinION and Flongle, hold great promise to impact 100 101 the clinical field. However, a major limitation has been the lack of analytical software featuring 102 standardized parameters to aid in translation into clinical diagnostics.

103

Here we report our success in developing an amplification-free CRISPR-Cas9 targeted enrichment sequencing protocol using Nanopore MinION and Flongles to detect fusions relevant in the diagnosis and classification of CML and AMLs. The ONT Flongle is an adaptor for the MinION that provides cost-effective (~\$90 per flow cell), real-time sequencing for smaller assays. Our assays were designed to capture varied breakpoints of CML and APL, as well as fusion genes resulting from inv(16) (*MYH11-CBFB*) and t(4;11)(*KMT2A-AF4*). Simultaneous

110 interrogation of these targets is a first step to a rapid characterization of AMLs in a single assay 111 combining data that up to now required multiple different techniques and provide relevant 112 information promptly. In addition to this amplification-free CRISPR-Cas9 nanopore assay, we extended our previously developed cloud-based nanopore data analysis pipeline <sup>13</sup> to include 113 114 fusion detection and develop a custom breakpoint detection tool (see Figure 1). Using our 115 optimized assay and our custom breakpoint finder, we showed that we can reliably detect and 116 confirm fusion breakpoints in 80% of our specimens in under 3 hours of sequencing and data 117 analysis.

118

119 Methods:

#### 120 Cells lines and patient samples

121 Our assay was optimized using 6 cell lines: three with the BCR-ABL1 fusion (K562, KU812, and KCL22), and NB4, MV4;11 and ME-1 that bear the PML-RARA, KMT2A-AF4, and MYH11-CBFB 122 123 fusions respectively. Residual mononuclear cells from primary specimens (6 specimens from 5 124 patients with CML, 6 specimens from 5 patients with suspected APL, and 2 acute myeloid leukemia, not acute promyelocytic leukemia) were isolated using Ficoll<sup>®</sup> reagent (Millipore-125 126 Sigma) and banked in liquid nitrogen until the time of the experiment. All specimens had been originally tested in a CLIA certified laboratory according to standard clinical protocols.<sup>14</sup> IRB 127 128 coverage was obtained for use of residual laboratory samples. Patient samples were deidentified to the nanopore testing lab, and cytogenetic or molecular results were confirmed 129 130 after nanopore results were rendered. Characteristics and demographics of specimens and patients are listed in Table 1. 131

132

### 133 Library preparation and sequencing assay

For the cell lines and 11/14 patient specimens the DNA was extracted with PureGene (Qiagen, 134 135 Germantown, MD, USA) following the standard protocol. Special caution, including use of wide 136 bore pipette tips and moderate centrifuge spin velocity was exercised to minimize fragmenting 137 DNA strands. Two DNA specimens were extracted with AllPrep DNA/RNA Kit (Qiagen, 138 Germantown, MD, USA), and one with QiAgen X-tractor with Reagent Pack DX (Qiagen, 139 Germantown, MD, USA). cRNA guides were designed to direct Cas9 to cut on genomic proximity 140 of each of the regions involved in each one of the translocations studied. When the target 141 region was big, guides were tiled across the region to maximize coverage. Guides were 142 designed to capture PML-RARA, BCR-ABL1 p210, KMT2A-AF4, and MYH11-CBFB, including 143 different fusion isoforms. Guides were designed using Chopchop 144 (https://chopchop.cbu.uib.no/) with the CRISPR-Cas9 and nanopore enrichment settings and previously described <sup>15</sup>. 145

146

We used 5 micrograms of DNA as input for each cell line and 2 to 5 micrograms for primary specimens. Average DNA integrity number (DIN) was 9.2 (range: 7.5-9.8). **Figure 1** shows a schematic of our workflow and details of the library prep are published<sup>15</sup>. Briefly, enrichment of target regions was obtained using Oxford Nanopore Technologies "Targeted, amplification-free DNA sequencing using CRISPR-Cas9" protocoll<sup>12</sup>. The different guides used in the assay were pooled in equimolar amounts of each guide. Through an initial dephosphorylation step, the 5' ends of the DNA becomes inaccessible to adapter ligation. Double stranded DNA breaks that

excise the region of interest are generated with the directional, target specific RNA guides 154 155 complexed with tracrRNA and Cas9 enzyme. The Cas9 complex remains bound to the 5' end of 156 the guide, and the resulting new DNA ends contain a phosphorylated 5' end that is available for dA tailing and adapter ligation.<sup>12</sup> All libraries generated in this manner were run on a MinION 157 158 version 9.4. (Oxford Nanopore Technologies, Oxford, UK) nanopore sequencer using flow cells 159 or Flongles. Modifications for libraries sequenced on the Flongle were only at the library loading 160 step, in which the amount of Sequencing Buffer and library beads (both SQK-LSK 109, ONT) are reduced to from 35 to 13 and 25.5 to 7.5UL respectively, and 0.5UL of SQT is added. QC 161 162 parameters tracked for each run are listed in Table 2.

163

#### 164 **PCR/Sanger sequencing**

Primers specific to *BCR-ABL1* patient breakpoints were designed using Primer3 v. 0.4.0.<sup>16</sup> in 2 cases. 100 ng of DNA were amplified, the PCR product was run on a 2% gel and Sanger sequenced to confirm the genomic breakpoint.

168

## 169 Biodepot-workflow-builder: Interactive and accessible front end for fusion detection

We present a graphical, reproducible, and cloud-enabled fusion detection workflow consisting of all the steps of the analyses, including base calling, alignment, fusion detection, and visualization (see **Figure 1 screenshot of BwB interface**). In contrast to the NanoFG workflow from Stangle et al<sup>17</sup>, our platform includes the computationally intensive base calling step, an interactive graphical user interface, and can readily leverage GPUs and be deployed on the cloud. Thus, analyses are fast, and our platform is accessible to biomedical and clinical

scientists. Specifically, we extended the Biodepot-workflow-builder (Bwb)<sup>18</sup> platform in which 176 177 each computational task (or module) is represented by a graphical widget that calls a software container in the back end. Software containers, such as Docker, include all software 178 dependencies and libraries required to execute the code. We have recently developed a Bwb 179 workflow<sup>13</sup> to support the processing of Nanopore data that includes the use of base callers 180 181 Guppy<sup>19</sup> and Bonito<sup>19</sup>, alignment using minimap2 and visualization of results using the Integrative Genomics Viewer (IGV) and GRCh37 hg19 as reference genome QC data was 182 generated with  $PycoQC^{20}$ . Guppy was used as the base caller. Minimap2<sup>21</sup> was used as the 183 aligner and variant caller. Fusions are visualized on IGV<sup>22</sup> and confirmed on Blast. Most 184 185 importantly, we extend our previous work by adding support for fusion detection, including LongGF<sup>23</sup> and our own custom software "Biodepot Fusion Finder" (BFF). 186

187

#### 188 Bioinformatics pipeline for fusion detection: LongGF

LongGF<sup>23</sup> is a software tool for fusion detection optimized for the high base calling error rates and alignment errors commonly found in long read sequencing data. LongGF takes as input a BAM file containing alignments (generated by minimap2 in this pipeline) and a GTF file containing the definitions of known genes. The output is a log file with detected gene fusions and their supporting reads. We created a graphical widget for LongGF in the Bwb. **Figure 2** shows a screenshot of the comparative workflows with output for LongGF versus BFF.

195

## 196 Custom fusion detection tool: Biodepot Fusion Finder (BFF)

197 Reads that span a fusion gene will align to coordinates in both parts of the fusion and provide a198 specific breakpoint coordinate. We wrote a new software tool, the Biodepot Fusion

199 Finder, BFF that examines the alternate alignments for each read and identifies reads that map 200 to coordinates spanning a set of known breakpoints. This is similar to the strategy used 201 by LongGF except that we allow for errors in the alignment near the breakpoint. Accordingly, 202 the Breakpoint Finder identifies fusions that are not detected by LongGF which looks for 203 supporting reads where the breakpoints are exactly matched. The user can provide a panel of 204 breakpoint coordinates of interest. If no panel is provided, BFF will return candidate fusions 205 that span nonadjacent genomic regions. Incomplete coordinates for breakpoints in the panel 206 are supported – the user does not need to define the exact coordinates, nor do both 207 breakpoints need to be given. BFF will return all the reads that match the panel of breakpoints 208 in a text file for further inspection by the user if desired. The user can also provide a file with 209 guide coordinates to obtain additional enrichment metrics. A containerized widget was 210 developed that can integrated with the Bwb workflows for processing nanopore data. Using 211 these workflows, we can directly analyze raw nanopore data and obtain lists of candidate 212 fusions.

213

#### 214 Benchmarking experiments

We performed empirical experiments to benchmark the sensitivity and runtime required to reliably detect fusion. For each individual sample, sequencing metrics including quality scores and timestamps are obtained from the sequencing summary text file obtained as an output of base calling using Guppy. Detected fusions are then acquired from the Breakpoint Finder as well as LongGF. Specific fusion breakpoints are also provided in the data set from the BFF. All samples are then combined into a dictionary and separated by patient and cell line data. Plots

are constructed for each category of data pertaining to the time to reach 3 fusions as well as
the number of reads required to reach 3 fusions. Finally, the total number of fusion reads
detected for each sample is compared between the BFF and LongGF as shown in Figure 2.

224

### 225 Enrichment assessment

226 Two enrichment metrics were computed by BFF and tracked for each sample. First is the fusion-227 specific enrichment which is calculated with the following formula [(number of fusion reads) / 228 (mean coverage of the genome)]. Second is the *on-target enrichment* which is calculated with 229 the following formula [(number of reads that originate from a guide RNA cut point that includes 230 the region of the breakpoint)/(mean genome coverage)]. Reads originating from a guide RNA 231 cut are distinguished by the guide sequence being at the beginning of a read. As initial electrical 232 signal data is generated by DNA passing through the nanopores (reads at the beginning of a 233 strand) are error prone, which affects base calling and therefore the alignment of the reads so 234 that the start sequence is often misaligned. Consequently, the BFF considers base pairs of the 235 sequence near the start (default within 50 bp) of a read that aligns near the coordinates of a 236 guide RNA cut site to have originated from a guide RNA cut. Specific reads cut by guides are 237 manually confirmed. The allowed error intervals are customizable. SamTools v1.13 is used to 238 sort and convert BAM files and determine the overall average coverage<sup>24</sup>. Picard CollectHsMetrics is used to generate the unique base pairs mapped metric for each sample<sup>25</sup>. 239

240

241 Results

#### 242 Sample sequencing and enrichment:

243 Details of the sample sequencing and enrichment metrics are included in Table 2. A range of 0.04 Gb - 5.47 gigabases of sequencing data was generated for each sample for an average 244 245 mean coverage of the human genome of 0.32-fold (range: 0.01 - 1.66). We adopted standard 246 quality metrics for nanopore workflows and tracked N50, which is a quality metric where half 247 the reads are above this length (range 4.65kb-32.2kb) and median read length for total reads 248 (range 0.87kb- 9.60kb). Percentage of reads aligned ranged from 72 - 96%. Fusion specific 249 enrichment was 135 - 837 fold for cell lines and 6 - 509 fold for patient samples. On target 250 enrichment was 849 - 5830 fold for cell lines and 535 - 3007 fold for patient samples.

251

#### 252 <u>Concordance of fusion detection with clinical results:</u>

253 Concordance with expected results was 100% for cell lines as the expected fusion was detected 254 in 6/6 cell lines (3 BCR-ABL1, 1 PML-RARA, 1 MYH11-CBFB, 1 KMT2A-AFF1). Breakpoint 255 sequences detected for BCR-ABL1 cell lines are the same as previously published <sup>26</sup>. We 256 correctly confirmed the presence or absence of fusions in 11/14 (78.5%) primary specimens 257 including both diagnostic and measurable residual disease (MRD) cases with a minimum of 258 three reads, however one case (APL6) showed only 2 fusion reads and was not counted as 259 confirmed. The 3 missed cases (CML3, APL1, and APL6 in tables 1 and 2) were comprised of low 260 disease burden, ~0%, 1% and <5%. We detected BCR-ABL1 in 5/6 cases, PML-RARA in 2/6 cases, 261 KMT2A-AF9 and CBFB-MYH11 in 1/1 case each. BCR-ABL1 genomic breakpoint was confirmed 262 by Sanger sequencing in CML1 and CML2 after designing patient specific primers.

263

264 In 3 specimens from 2 patients with suspected APL, we could not detect PML-RARA but 265 observed other findings. Clinical and laboratory details are listed in **Table 2**. For the first patient, 266 two specimens, one bone marrow and one peripheral blood (APL4 and APL 5) yielded no PML-267 RARA fusion reads. This patient presented with an AML morphologically suggestive of APL and 268 an isochromosome 17q without t(15;17) detected by karyotype. While fusion detection 269 software did not detect a fusion, manual inspection showed an insertion in an intronic region of RARA with TTMV viral genome; this case was previously reported<sup>15</sup>. Patient APL6 (presented 270 271 with 22% blasts on flow in a <5% marrow which on unblinding showed a complex karyotype 272 with t(11;17)(q23;q25) including the KMT2A gene. Two reads with KMT2A-SEPT9 fusion were 273 detected in a suboptimal but acceptable run (N50 < 5000bp; on-target enrichment 650.66 fold), 274 confirming the lack of t(15;17) or PML-RARA fusion but the threshold was below the requisite 3 275 reads to confirm the KMT2A-SEPT9 fusion.

276

#### 277 <u>Comparison of fusion detection tools:</u>

278 A comparison of the bioinformatic workflows for data analysis using different fusion detection 279 widgets including LongGF vs Biodepot Fusion Finder (BFF) was conducted; the specific workflow 280 is demonstrated in Figure 2. Additionally, BFF computes the fusion enrichment and on target 281 enrichment statistics; these are summarized in Table 2. In most cell line and primary specimens, 282 LongGF shows a particular challenge in the detection of BCR-ABL1 and does not detect all fusion 283 reads that are identified by BFF. Using the BFF, the average sequencing, and data processing 284 time to 3 reads with fusions in the cell line experiments was 42.75 minutes (range: 18.87 - 77.65 285 min) and 188 minutes in the primary specimens where 3 reads were detected (range: 32 - 654

min) [see Figure 3, and Supplemental Table 1]. Cell line experiments took an average of 11,711

reads to identify 3 fusion reads (range: 1,321 – 43,326 reads) and 10,273 reads in primary

specimens (range: 1,790 - 24,999 reads) for confirmation of the fusion calls.

289

#### 290 Comparison of Flongles and flow cells:

291 In five of our experiments (2 cell lines, 3 primary specimens), we used Flongles, while in the rest 292 we used Flow Cells. The performance of the affordable Flongles was inferior to the Flow Cells, 293 with lower expected average data output from the Flongles (based on manufacture 294 expectations of ~3GB), the N50 and median read length were smaller in Flongle reads (21,614 295 vs 19,166 and 6058 vs 5250 respectively), and significantly, the median Phred score for Flongle 296 reads being lower than that for the Flow Cells (9.2 vs 11.88). Despite the worse performance of 297 the Flongles, fusions were detected in 2 of 2 cell lines, and 2 of the 3 experiments with primary 298 specimens with at least 8 and 14 reads confirming the fusion and the specimen without fusion 299 confirmation was CML3 with pancytopenia and low disease burden.

300

## 301 Discussion

We developed a rapid assay to detect fusion genes in blood or marrow samples in less than 8 hours with the fastest time achieving 3 fusion reads was 5 hours. This was accomplished by combining CRISPR-Cas9 enrichment during library preparation, nanopore long-read sequencing, a cloud-based data analytic pipeline, with a novel BFF program developed and optimized for finding fusions reads and breakpoints. RNA guides were designed to target genes involved in recurrent fusions in myeloid malignancies and used to enrich an amplification-free library

308 preparation over 1600-fold. Our modular and containerized pipeline in Bwb allows users to 309 efficiently process raw FAST5 data on the cloud through an accessible graphical user interface 310 allowing for a very fast analysis step (average  $\sim$ 4.5 minutes for basecalling, alignment, and 311 fusion detection). To improve fusion calling, we developed the custom BFF that allow users to 312 identify fusion reads not detected by LongGF. We successfully confirmed published genomic 313 breakpoints in our series of cell lines and archival patient samples, which includes both 314 diagnostic and follow-up samples to test feasibility in confirming both common and novel 315 fusions over a range of tumor burdens. Our study includes 14 patient specimens and 316 demonstrates the usability of this method in primary specimens with 2microgram of DNA.

317

318 An advantage of the CRISRP-Cas9 based enrichment protocol is that it allows for targeting of 319 multiple common leukemia fusion genes by pooling multiple guide RNAs. Fusions are 320 particularly well suited for this method as they have large gene segments that aid in alignment 321 despite sequencing errors and wide variation where translocation breakpoints may occur. 322 Other labs have employed similar but different methods that detected fusions by targeting one 323 partner gene in the fusion <sup>17</sup>. In contrast, our assay targets both partners of the fusion thus our 324 approach allows for an expanded capability to detect known and novel fusions, such as in case 325 AML1 with t(9;11), when guides are designed to target t(4;11). However, in 2/14 patients the 326 assay did not detect fusion genes because both cases had a very low amount of fusion target. In 327 one case (CML3) because the BCR-ABL1 was <0.01%, the other in the context of a very 328 hypocellular sample.

330 Our work differs from standard RNA-based fusion detection assays, and instead interrogated 331 single molecules of DNA rapidly and accurately to detect specific translocation breakpoints. Long-read sequencing technologies, like nanopore (Oxford Nanopore Technologies, Oxford, 332 333 U.K.), allow sequencing of unamplified, long unbroken fragments of DNA which are more likely 334 to span a breakpoint. This has potential clinical utility for personalized disease monitoring when CML patients are on TKI therapy and suppressing RNA transcription<sup>27</sup>; targeting DNA as a 335 monitoring target may be more robust and reproducible since DNA is stable and present in 336 constant numbers<sup>28</sup>. However genomic breakpoints in *BCR-ABL1* are unique to individual 337 patients requiring patient-specific breakpoint characterization<sup>28-32</sup> as *ABL1* breakpoints occur 338 339 over an expansive region of about 150Kb, making this is an arduous endeavor previously involving multiple primer sets and Sanger sequencing<sup>33</sup>. Our method allows a single approach 340 341 spanning the BCR and ABL1 breakpoint regions without the use of multiple primers and PCR 342 reactions. The sensitivity of DNA-based gPCR once the breakpoint is known can be as low as 10<sup>-</sup> <sup>7 34-35</sup>. Specimens CML1 and CML5 are a BM and PB obtained from the same patient and 343 344 demonstrate high fidelity in confirming genomic breakpoints and the ability to use patient 345 specific primers for personalized MRD monitoring.

346

Advantages of long-read sequencing over current clinical diagnostic assays are speed and the relatively low complexity of the assay when compared to cytogenetics and targeted NGS panels. While long-read sequencing results could potentially have a turnaround time (TAT) of less than 24 hours, full karyotype analysis TAT is generally longer with the fastest times at days to a week and most targeted NGS panels require ~7-10 days from start of processing to result

352 report. The nanopore sequencing streams data simultaneously to our GPU-enabled data 353 analytic pipeline in the Bwb interface which resides on the cloud to help interpret and reliably 354 identify fusion reads within 5000 seconds(<2 hours) computational time in most specimens. Building on our experience<sup>14,17</sup>, we used 3 reads as a threshold for fusion confirmations. With 355 356 current simultaneous sequencing and data analysis workflow described here, 3 sequences are 357 detected in an average of 3 hours and 7 min (fastest at 30 min) in the 9 patient specimens 358 where a fusion could be confirmed. This means that a diagnostic result with a precise fusion 359 breakpoint with 3 fusion supporting reads would be possible in the same day.

360

361 Five specimens were sequenced on the less costly Flongle device, which has lower sequencing 362 capabilities (pore count  $\sim$ 60, sequencing life 24h), but 3 fusion reads were reached in 4/5 363 specimens (2 cell lines, 3 patient samples) with less resources. The sequencing quality is 364 significantly lower on the Flongles (median Phred 9.2 in Flongles vs 11.9 in Flow Cells), however 365 fusions were detected in all samples with adequate tumor burden. To achieve a cheaper 366 version of our fast and portable nanopore fusion assay, further challenges will need to be 367 addressed. We predict overall less sequencing can be achieved, even with additional 368 optimizations of the CRISPR library guides as multiplexing of the guide RNA appears to increase 369 efficiency and on-target fusion reads. Nanopores on the Flongles have poorer viability and 370 generate more read errors demonstrable by lower Flongle Phred quality on average and 371 therefore additional alignment challenges and a study of errors specific in Flongle bioinformatic 372 data compared to the flow cells are needed to understand potential compensation mechanisms 373 for data analysis.

374

#### 375 Conclusion

376 We demonstrate the feasibility of using single molecule long-range sequencing assay to detect 377 fusion genes in heme malignancy (AML, CML and APL) patients. Inherent characteristics of 378 fusions make this assay a promising cost effective tool for rapid detection of recurrent fusions 379 that 1) does not require previous knowledge of the target, , 2) with a rapid TAT (8 hours in 80% 380 of samples) when multiplexing different assays and used with the specific data analysis and fusion detection tools described in our manuscript, 3) can precisely map translocation genomic 381 382 breakpoints that allow for development of personalized markers for disease monitoring, and 4 383 ) can potentially allow discovery of novel/different fusion partners

384

**Contributions:** OST and CY designed the study and performed background research and secured IRB protocol. KYY and LHH designed the informatics pipeline and algorithms. JR, DW and CY identified specimens. LHH and SR implemented the software. SR, OST and CY tested the software. OST, LB, SR, LHH, CY performed research and analyzed the data. KYY, JR, CY funded the project and provided supervision. OST, SR, KYY, and CY drafted the manuscript. All authors reviewed and edited the manuscript.

391

#### 392 Funding

This study was supported in part by NCCN young investigator award and the Hyundai Hope on Wheels Scholars Award, R01 CA175008-06, UG1 CA233338-02, and Adult Leukemia Research Center Grant # P01 CA018029 as funded by the National Cancer Institute, National Institutes of

396	Health, Bethesda, MD. LHH, SR and KYY are supported by NIH grant R01GM126019. SR is also												
397	supported by the Vicky L. Carwein and William B. Andrews Endowments for Graduate												
398	Programs.												
399													
400	Disclosures: LHH and KYY also have equity interest in Biodepot LLC, which receives												
401	compensation from NCI SBIR contract numbers 75N91020C00009 and 75N91021C00022.												
402													
403	Acknowledgements: The authors want to thank Dr Phillip E. Starshak, Kaiser Permanente												
404	Oakland, for procuring specimens.												
405													
406	References:												
407	1. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health												
408	Organization classification of myeloid neoplasms and acute leukemia. Blood. May 19												
409	2016;127(20):2391-405. doi:10.1182/blood-2016-03-643544												
410	2. Quessada J, Cuccuini W, Saultier P, Loosveld M, Harrison CJ, Lafage-Pochitaloff M.												
411	Cytogenetics of Pediatric Acute Myeloid Leukemia: A Review of the Current Knowledge. Genes												
412	<i>(Basel)</i> . Jun 17 2021;12(6)doi:10.3390/genes12060924												
413	3. Hehlmann R. Innovation in hematology. Perspectives: CML 2016. Haematologica. Jun												
414	2016;101(6):657-9. doi:10.3324/haematol.2016.142877												
415	4. Lo-Coco F, Cicconi L. History of acute promyelocytic leukemia: a tale of endless												
416	revolution. Mediterr J Hematol Infect Dis. 2011;3(1):e2011067. doi:10.4084/MJHID.2011.067												

417	5. Long ZJ, Hu Y, Li XD, et al. ATO/ATRA/anthracycline-chemotherapy sequential
418	consolidation achieves long-term efficacy in primary acute promyelocytic leukemia. PLoS One.
419	2014;9(8):e104610. doi:10.1371/journal.pone.0104610
420	6. Amarasinghe SL, Su S, Dong X, Zappia L, Ritchie ME, Gouil Q. Opportunities and
421	challenges in long-read sequencing data analysis. <i>Genome Biol</i> . Feb 7 2020;21(1):30.
422	doi:10.1186/s13059-020-1935-5
423	7. Jain M, Koren S, Miga KH, et al. Nanopore sequencing and assembly of a human genome
424	with ultra-long reads. Nat Biotechnol. Apr 2018;36(4):338-345. doi:10.1038/nbt.4060
425	8. Fox EJ, Reid-Bayliss KS, Emond MJ, Loeb LA. Accuracy of Next Generation Sequencing
426	Platforms. Next Gener Seq Appl. 2014;1doi:10.4172/jngsa.1000106
427	9. Jancuskova T, Plachy R, Zemankova L, et al. Molecular characterization of the rare
428	translocation t(3;10)(q26;q21) in an acute myeloid leukemia patient. <i>Mol Cytogenet</i> . 2014;7:47.
429	doi:10.1186/1755-8166-7-47
430	10. Jeck WR, Lee J, Robinson H, Le LP, lafrate AJ, Nardi V. A nanopore sequencing-based
431	assay for rapid detection of gene fusions. J Mol Diagn. Sep 28
432	2018;doi:10.1016/j.jmoldx.2018.08.003
433	11. Jain M, Fiddes IT, Miga KH, Olsen HE, Paten B, Akeson M. Improved data analysis for the
434	MinION nanopore sequencer. Nat Methods. Apr 2015;12(4):351-6. doi:10.1038/nmeth.3290
435	12. Gilpatrick T, Lee I, Graham JE, et al. Targeted nanopore sequencing with Cas9-guided
436	adapter ligation. Nat Biotechnol. Apr 2020;38(4):433-438. doi:10.1038/s41587-020-0407-5

Reddy S, Hung LH, Sala-Torra O, Radich JP, Yeung CC, Yeung KY. A graphical, interactive
and GPU-enabled workflow to process long-read sequencing data. *BMC Genomics*. Aug 23

439 2021;22(1):626. doi:10.1186/s12864-021-07927-1

Yeung C, Qu X, Sala-Torra O, Woolston D, Radich J, Fang M. Mutational profiling in acute
lymphoblastic leukemia by RNA sequencing and chromosomal genomic array testing. *Cancer Med.* Aug 2021;10(16):5629-5642. doi:10.1002/cam4.4101

443 15. Sala-Torra O, Beppu LW, Abukar FA, Radich JP, Yeung CC. TTMV-RARA fusion as a 444 recurrent cause of AML with APL characteristics. Blood Adv. Apr 14 445 2022;doi:10.1182/bloodadvances.2022007256

446 16. Bioinformatics Methods and Protocols: Methods in Molecular Biology. . Humana Press;

447 17. Stangl C, de Blank S, Renkens I, et al. Partner independent fusion gene detection by

448 multiplexed CRISPR-Cas9 enrichment and long read nanopore sequencing. *Nat Commun*. Jun 5

449 2020;11(1):2861. doi:10.1038/s41467-020-16641-7

450 18. Hung LH, Hu J, Meiss T, et al. Building Containerized Workflows Using the BioDepot-

451 Workflow-Builder. Cell Syst. Nov 27 2019;9(5):508-514 e3. doi:10.1016/j.cels.2019.08.007

452 19. Wick RR, Judd LM, Holt KE. Performance of neural network basecalling tools for Oxford

453 Nanopore sequencing. *Genome Biol*. Jun 24 2019;20(1):129. doi:10.1186/s13059-019-1727-y

454 20. Leger AL, T. pycoQC, interactive quality control for Oxford Nanopore Sequencing. 455 *Journal of Open Source Software*. 2019;4(34):1236.

456 21. Li H. Minimap2: pairwise alignment for nucleotide sequences. *Bioinformatics*. Sep 15

457 2018;34(18):3094-3100. doi:10.1093/bioinformatics/bty191

458 22. Robinson JT, Thorvaldsdottir H, Winckler W, et al. Integrative genomics viewer. Nat
459 Biotechnol. Jan 2011;29(1):24-6. doi:10.1038/nbt.1754

460 23. Liu Q, Hu Y, Stucky A, Fang L, Zhong JF, Wang K. LongGF: computational algorithm and

461 software tool for fast and accurate detection of gene fusions by long-read transcriptome

462 sequencing. BMC Genomics. Dec 29 2020;21(Suppl 11):793. doi:10.1186/s12864-020-07207-4

463 24. Li H, Handsaker B, Wysoker A, et al. The Sequence Alignment/Map format and

464 SAMtools. *Bioinformatics*. Aug 15 2009;25(16):2078-9. doi:10.1093/bioinformatics/btp352

465 25. Picard Toolkit. Broad Institute, GitHub repository.

26. Ross DM, Schafranek L, Hughes TP, Nicola M, Branford S, Score J. Genomic translocation
breakpoint sequences are conserved in BCR-ABL1 cell lines despite the presence of
amplification. *Cancer Genet Cytogenet*. Mar 2009;189(2):138-9.
doi:10.1016/j.cancergencyto.2008.10.010

Pagani IS, Dang P, Kommers IO, et al. BCR-ABL1 genomic DNA PCR response kinetics
during first-line imatinib treatment of chronic myeloid leukemia. *Haematologica*. Dec
2018;103(12):2026-2032. doi:10.3324/haematol.2018.189787

473 28. Ross DM, Branford S, Seymour JF, et al. Patients with chronic myeloid leukemia who 474 maintain a complete molecular response after stopping imatinib treatment have evidence of 475 persistent leukemia by DNA PCR. Leukemia. Oct 2010;24(10):1719-24. 476 doi:10.1038/leu.2010.185

29. Zhang JG, Lin F, Chase A, Goldman JM, Cross NC. Comparison of genomic DNA and cDNA
for detection of residual disease after treatment of chronic myeloid leukemia with allogeneic
bone marrow transplantation. *Blood*. Mar 15 1996;87(6):2588-93.

480 30. Mattarucchi E, Spinelli O, Rambaldi A, et al. Molecular monitoring of residual disease in

- 481 chronic myeloid leukemia by genomic DNA compared with conventional mRNA analysis. J Mol
- 482 *Diagn*. Sep 2009;11(5):482-7. doi:10.2353/jmoldx.2009.080150
- 483 31. Bartley PA, Latham S, Budgen B, et al. A DNA real-time quantitative PCR method suitable
- 484 for routine monitoring of low levels of minimal residual disease in chronic myeloid leukemia. J

485 *Mol Diagn*. Mar 2015;17(2):185-92. doi:10.1016/j.jmoldx.2014.10.002

- 486 32. Bartley PA, Ross DM, Latham S, et al. Sensitive detection and quantification of minimal
- 487 residual disease in chronic myeloid leukaemia using nested quantitative PCR for BCR-ABL DNA.

488 Int J Lab Hematol. Dec 2010;32(6 Pt 1):e222-8. doi:10.1111/j.1751-553X.2010.01236.x

- 489 33. Cumbo C, Anelli L, Specchia G, Albano F. Monitoring of Minimal Residual Disease (MRD)
- 490 in Chronic Myeloid Leukemia: Recent Advances. *Cancer Manag Res.* 2020;12:3175-3189.
- 491 doi:10.2147/CMAR.S232752

34. Burmeister T, Marschalek R, Schneider B, et al. Monitoring minimal residual disease by
quantification of genomic chromosomal breakpoint sequences in acute leukemias with MLL
aberrations. *Leukemia*. Mar 2006;20(3):451-7. doi:10.1038/sj.leu.2404082

495 35. Branford S. Molecular monitoring in chronic myeloid leukemia-how low can you go?
496 *Hematology Am Soc Hematol Educ Program*. Dec 2 2016;2016(1):156-163.
497 doi:10.1182/asheducation-2016.1.156

- 499
- 500
- 501

#### 502 Figure and Table legends:

503

504 **Figure 1.** Chemistry and bioinformatics workflow of rapid single molecule long-read 505 sequencing.

506 Genomic DNA may contain a target fusion gene. The CRISPR-Cas9 system binds via 507 specific guideRNA (gRNA) designed to enrich for DNA containing regions of interests. The library 508 preparation does not undergo any amplification, and simply requires dA tailing and adapter ligation and a clean-up prior to being loaded onto a sequencing flow cell. On the flow cell 509 510 libraries are sequenced by nanopores. Data from the sequencing devices are streamed 511 onto biodepot workflow builder and are analyzed starting from FAST5 files, through an initial 512 quality control, then base calling and alignment. After alignment different fusion finder tools 513 were tested including LongGF and BFF before visualizing on IgV for confirmation and 514 interpretation.

515

Figure 2. Screenshot of our bioinformatics workflow and output. Panel A: Bwb workflow
showing the workflow including our custom Biodepot Fusion Finder (BFF) and LongGF widgets.
Panel B: shows enrichment statistics as fusion enrichment and on target enrichment. Panel C:
alignment can be viewed on IGV based on a BAM file generated from minimap2. This case
shows a t(9;22) *BCR-ABL1* fusion in a primary specimen. Reads spanning the breakpoint are
colored with the same color on alignment to both genes.

522

523 **Figure 3.** Time required to obtain 3 fusion supporting reads.

524	Top panel shows the time to 3 fusion supporting reads seen in the cell lines samples. Bottom
525	panel shows time to 3 fusion supporting reads seen in patient samples. Details of specific times
526	are listed in supplementary table 1.
527	
528	Table 1. Characteristics of the Primary Specimens analyzed
529	
530	Table 2. Characteristics of the Runs
531	
532	Supplementary Table 1. Times and total reads before 3 fusion reads could be confirmed in cell

533 lines and patient samples.

Figure 1.



## Figure 2.

A: Bwb workflow with LongGF & BFF

File Edit View Widget ToolDock								
Ca RNA-seq								
X Utilities		-						
Miscellaneous								
😧 User	start	11						
遵 Jupyter	1	111						
Scripting	Download	( <u>+</u> )	-(±)					
BiodepotFusionFinder								
		Download Genome	Download fast5 files					
II 🖉 📈								
gnum Biode		(8)	400	o <u>\$</u>	Biodep	pot Fusion Finder	-	
fusion-nanopore	Call bases	10x	-150	Required entries Optional entries	Scheduler	Console		
		Setup guppy	Guppy (proprietary basecaller)	Breakpoints file:	Enter file			-15
				Guides file:	Enter file			3
		V(		Breakpoints (eg 'chr15:::chr17::'):				
	Align	( see s	A MARTINE A					
		( mail			Enter parama	eter	46	
	1 -	Index (Minimap2)	Align (Minimap2 + Samtools)	Minimum mapq score		50		\$
				Max length of fusion overlap		20		\$
				Max length of fusion gap		80		0
	Find Fusions	40	LGE	Nearby breakpoint distance		100		\$
				Max dist guide can be from read er	nd	50		\$
DiadapatEurianEinder		Biodepot Fusion Finder	LongGF	Minimum supporting reads		3		\$
Minimum and container				Calculate enrichment				
more and per container	Visualize		1000	File is unsorted				Ŧ
		400	Igv	Start Stop Use gpu E	Export graphic	cs Test mode Runt	tode: Manual + Select Trig	gers,
		View fusions	View alignments	2				
; # T`\`II 📀								

#### B: Enrichment statistics computation output

	Α	В	C	D	E	F	G	н	1	J
1	Breakpoint	Gap/Overlap	Count	Nearby-count	ReadThru	NearbyReadThru	Breakpoint enrichment	Breakpoint nearby enrichment	Fraction on target	Fraction on target nearby
2	chr9:133607156;chr22:23632742		1	29	30	31	30.19597	875.68318	0.03333	0.93548
3	chr9:133607152;chr22:23632739	4	1 1	29	29	31	30.19597	875.68318	0.03448	0.93548
4	chr9:133607147;chr22:23632742		21	29	28	31	634.11541	875.68318	0.75000	0.93548
5	chr9:133607164;chr22:23632742		i 1	29	31	. 31	30.19597	875.68318	0.03226	0.93548
6	chr9:133607168;chr22:23632748	5	i 1	29	30	31	30.19597	875.68318	0.03333	0.93548
7	chr9:133607158;chr22:23632736	8	8 1	29	31	. 31	30.19597	875.68318	0.03226	0.93548
8	chr9:133607147;chr22:23632715	16	5 1	29	31	. 31	30.19597	875.68318	0.03226	0.93548
9	chr9:133607177;chr22:23632748	17	1	29	30	31	30.19597	875.68318	0.03333	0.93548
10	chr9:133607153;chr22:23632728	20	1	29	31	. 31	30.19597	875.68318	0.03226	0.93548
11	Coverage	MaxBpFromEnd	d GuideReads	Enrichment						
12	0.0331	50	212	6401 546						

# C: IGV image confirming fusion





Figure 3.

#### Table 1- Characteristics of the Primary Specimens analyzed

Patient Code	Age	Gender	Diagnosis	Specimen Source	Disease Burden	Cytogenetics/Molecular
CML1	61 - 65	Male	CML-AP Rlps	BM	2% blasts	46,XY,t(5;12)(q33;q15),t(9;22)(q34;q11.2)[2]/47,sl,+8[18]
CML2	41 - 45	Female	CML-BC	РВ	NA	Outside cytogenetics confirmed t(9;22) but only in 3/21 karyotypes. Full karyotype not available.
CML3	56 - 60	Male	CML-AP	РВ	NA	Patient with long standing p190 CML. At this time-point sample presents MDS/MPN with low level BCR-ABL1 by PCR.
CML4	21 - 25	Male	CML-CP	РВ	3% blasts	46,XX,t(9;22)(q34;q11.2)[20]
CML5	61 - 65	Male	CML-AP Rlps	PB	3% blasts	46,XY,t(5;12)(q33;q15),t(9;22)(q34;q11.2)[2]/47,sl,+8[18]
CML6	65 - 70	Female	CML-BC	PB	16% blasts	46,XX,t(9;22)(q34:q11.2)[4]; Confirmed by molecular studies.
AML1	36 - 40	Male	AML	PB	90% blasts	46,XY,t(9;11)(q21;q23)[20]
AML2	36 - 40	Female	AML	РВ	20% blasts	47,XX+8,inv(16)(p13.1q22)[17]/46,XX[3]
APL1	81 - 85	Male	APL	РВ	<1% blasts	Patient with collision Multiple Myeloma and APL in BM with 30% blasts, not available for analysis. No circulating APL in PB.
APL2	31 - 35	Female	APL	BM	80% blasts	46,XX,der(2)t(2;17)(q33;q21)t(15;17)(q22;q21),der(15)t(15;17),der(1 7)t(2;17)[3]/47,sl+8[3]/48,sdl,+8[12]/46,XX[2]
APL3	21 - 25	Male	APL	РВ	75% blasts	NA
APL4	36 - 40	Male	APL	BM	83% blasts	AML with isochromosome 17q
APL5	36 - 40	Male	APL	РВ	79% blasts	AML with isochromosome 17q
APL6	41 - 45	Male	APL	BM	22% blasts in a <5% marrow	46, XY,t(1;7)(q21;q21), t(4;10)(q21;q25), add(8)(p23), del(9)(p22), t(11;17)(q23;q25)[4]/46, XY[16} from 3 months prior

CML= Chronic Myeloid Leukemia; AML= Acute Myeloid Leukemia; APL= Acute Promyelocytic Leukemia, AP= Accelerated Phase, BC= Blast Crisis, PB= Peripheral Blood, BM= Bone Marrow; NA= not available

#### Table 2. 2. Characteristics of the Sequencing Runs

												On-	Fusion	
			Gb of D	Mean Cove			Median Rea	Median P	% Reads Alig	Fusion Reads	- Fusion Reads -	target Enri	Enrichment spanning	
Sample	DIN	Device	ata	rage	All Reads	N50 All Reads	d Length	HRED	ned	LongGF	BFF	chment	breakpoint	Disease Burden
K562	9.8	Flongle	0.12	0.04	35943	5980	2200	9.516	87.57	0	29	5830.00	797.50	NA
KU812	8.7	Flowcell	0.36	0.11	86579	9690	1820	12.759	96.29	0	51	2108.33	467.50	NA
KCL22	9.7	Flowcell	0.69	0.21	50439	32200	6290	12.259	91.86	5	171	2118.70	817.83	NA
NB4	9.1	Flongle	0.07	0.02	23122	5890	1450	9.133	88.86	3	3	848.57	141.43	NA
MV4;11	8.6	Flowcell	0.28	0.08	40000	27100	1890	11.98	89.34	57	71	2698.93	836.79	NA
ME1	8.2	Flowcell	0.91	0.28	433846	16500	872	11.17	84.69	45	37	1305.49	134.18	NA
CML1	9.8	Flowcell	0.92	0.28	32723	24600	9600	12.309	91.74	0	142	1563.91	509.35	CML-AP Relapse
CML2	9.6	Flowcell	0.04	0.01	4026	22400	6520	11.148	72.08	0	4	2227.50	330.00	CML BC
CML3	9.8	Flongle	0.09	0.03	9857	19900	5860	9.45	85.54	0	0*	3006.67	NA	CML-AP
CML4	9.7	Flongle	0.93	0.28	109648	15200	1800	9.314	85.97	0	14	557.10	49.68	CML-CP
CML5	ND	Flongle	0.04	0.03	3907	22400	8090	8.95	91.06	0	8	1283.33	293.33	CML-AP Relapse
CML6	9.2	Flowcell	5	1.52	381552	30800	7090	11.94	90.73	0	in	1539.12	142.56	CML BC
AML1	9.3	Flowcell	5.47	1.66	639884	15100	6340	9.89	86.76	28	38	535.12	22.93	90% blasts
AML2	9.2	Flowcell	1.59	0.48	161010	19400	6540	12	89.95	0	0	649.62	NA	20% blasts
														0% blasts in PB, APL
														confirmed by FISH on
APL1	9.6	Flowcell	0.17	0.05	13486	24700	7450	12.942	92.49	0	0**	1242.35	NA	BM sample
APL2	7.76	Flowcell	1.1	0.33	40919	24200	8770	12.12	92.69	8	10	618.00	30.00	80% blasts
APL3	9.7	Flowcell	0.31	0.09	13625	22500	6910	12.422	93.51	8	10	872.90	106.45	75% blasts
APL4	9.6	Flowcell	1.63	0.49	176665	25200	3740	12.38	93.27	0	0***	1785.64	NA	83% blasts
APL5	9.3	Flowcell	0.22	0.07	31863	24200	2450	11.82	91.49	0	0***	2520.00	NA	79% blasts
														22% blasts on flow in
APL6	7.5	Flowcell	1.06	0.32	485374	4650	1230	11.7	84.27	0	2****	650.66	6.23	a <5% marrow

\* Pt had very low BCR-ABL1 levels that was only detected by qualitative PCR and not quantitative PCR (meaning below 0.01%)

\*\* Pt with confirmed BM disease but PB sample that is used for this assay had <1% blast count.

\*\*\* Pt had an unusual fusion between a viral gene and RARA(reference: Sala-Torra, Blood Adv. Apr 14 2022), however a human reference genome was used on BFF to generate this data and thus this fusion could not be detected.

\*\*\*\* Pt was suspected to have APL, but subsequent cytogenetic results showed complex karyotype with an unexpected KMT2A fusion and this was a challenged sample with an N50 below 5000bp.

CML= Chronic Myeloid Leukemia; AML= Acute Myeloid Leukemia; APL= Acute Promyelocytic Leukemia, AP= Accelerated Phase, BC= Blast Crisis, PB= Peripheral Blood, BM= Bone Marrow; NA= not available FISH = fluorencence in-situ hybridization